Moderna

The Wendy's

Enbridge

Inflation, Earnings and Currency Dynamics: What to Watch on February 13th

Cameco

TC Energy

Alaska Air Group

Earnings Preview: Enbridge, Moderna, Cameco, and More

Moderna's Stock Down 10% After FDA Declines to Review New Influenza Vaccine Application

Moderna's Options Market Reflects Mixed Sentiment Amid Price Decline

Moderna Shares Plummet After FDA Rejects Flu Vaccine Application

Catalyst<ul> <li>Most analysts rate MRNA Neutral, indicating some level of cautious optimism amid broader pessimism.</li> <li>The company maintains strong cash reserves relative to market value, offering a buffer against near-term financial pressures.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant, with no recent bullish patterns observed in the technical analysis.</li> <li>There are differences in analyst ratings, indicating a lack of consensus and uncertainty about the company’s outlook.</li></ul>

Key Factors

FDA refuses to review Moderna's influenza vaccine application due to comparator concerns.Moderna's stock drops 9.51%-10.73% following the FDA's rejection of its flu vaccine application.Moderna signs a 5-year agreement with the Mexican government for vaccine supply and tech transfer, causing a 5.15% intraday stock price increase.

Recent Updates

MRNA News